Amgen, CytomX Launch Up-to-$1.465B+ Cancer Immunotherapy Collaboration – Genetic Engineering & Biotechnology News
|
Amgen, CytomX Launch Up-to-$1.465B+ Cancer Immunotherapy Collaboration
Genetic Engineering & Biotechnology News Amgen will use CytomX's Probody™ therapeutics platform to develop new cancer immunotherapies under a collaboration that could generate up to $1.465 billion-plus for CytomX. Amgen and CytomX have agreed to codevelop a CytomX Probody … |
